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ABSTRACT
Excessive weight gain, hypertension, hyperlipidemia, and diabetes are frequently
observed among orthotopic liver transplantation (OLT) patients. These alterations,
which are probably multifactorial in origin, contribute to posttransplantation meta-
bolic syndrome (PTMS), which increases the risk of cardiovascular events. We assessed
the prevalence of PTMS (diagnosed according to modified NCEP Adult Treatment
Panel III criteria) in 156 OLT patients undergoing regular follow-up after transplan-
tation (median 68 months; range, 6 to 234 months). Several pre- and post-OLT data
were collected to identify the factors associated with the presence of PTMS which was
found in 28% of cases. The only independent predictive factors for PTMS were
diabetes mellitus and patients who were overweight or obese before-OLT. The
prevalence of PTSM was lower among patients on tacrolimus immunosuppression. In
our population, 21% of patients showed a high cardiovascular risk score with a 4%
incidence of cardiovascular events, which was higher among subjects with PTMS. Close
follow-up is mandatory to prevent the development of PTMS mainly among overweight
and diabetic patients before transplantation.BECAUSE of improved survival after orthotopic livertransplantation (OLT), greater attention has been
given to the diseases occurring in long-term follow-up.
Metabolic syndrome (MS), as defined by National Cho-
lesterol Education Program Adult Treatment Panel III
criteria,1 is characterized by a cluster of manifestations
ncluding obesity, arterial hypertension, hyperglycemia,
nd dyslipidemia. After OLT, the prevalence of diabetes
ises from 15% prior to OLT to 30-40% after transplan-
ation, while hypertension increases from pre-transplant
revalence of 15% to 60-70% after transplantation (ref-
rence 2). The reported prevalence of dyslipidemia after
ransplantation is about 50-70%.2 Previous studies have
eported posttransplant metabolic syndrome (PTMS)
mong 44% to 58% of patients after transplantation3,4
and is associated with an increased risk of cardiovascular
and cerebrovascular events.5 Several predictors for
TMS have been identified as potential risk factors:
igher age at transplant, male gender, pre-OLT diabetes/
besity, the etiology of the underlying liver disease, and
he choice of immunosuppressive agents.3–6 To improve
survival among transplanted patients requires preventive
measures, early recognition, and treatment of risk fac-
tors. We evaluated the prevalence and incidence of
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Transplantation Proceedings, 44, 2005–2006 (2012)PTMS to recognize risk factors for its development and
to examine its association with cardiovascular risk.
METHODS
Adult stable-OLT recipients who were transplanted between 1990
and 2010 and continuously followed in our unit as outpatients were
enrolled between April 2009 and August 2010. We excluded
patients with low compliance, lack of clinical information, or less
than 6 months follow-up. Demographic, lifestyle and socioeco-
nomic data (age, sex, marital status, professional activity and
education, smoking habits) and clinical data (time since OLT,
indication for OLT, length of time on steroids after OLT, immu-
nosuppressive therapy, arterial hypertension, and diabetes melli-
tus) were collected from our medical records. We also evaluated
nutritional data before and during follow-up after OLT. PTMS was
defined according to the modified NCEP Adult Treatment Panel
III (ATPIII) criteria, wherein waist circumference was replaced
with body mass index 28.8. For each patient we retrospectively
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2006 IADEVAIA, GIUSTO, GIANNELLI ET ALinvestigated time of appearance of each factor within the diagnosis
of MS. Individual cardiovascular risk was also calculated using an
Italian questionnaire available on www.cuore.iss.it. Student t test as
ell as univariate and multivariate analyses were used to investi-
ate the individual role of each risk factor to determine PTMS. A
value .05 was considered statistically significant.
RESULTS
We studied 156 patients including 76% males with an
overall median age of 59 years. Their median time since
transplantation was 68 months (range, 6 to 234 months).
The main indications for liver transplantation were hepati-
tis C (38%), hepatitis B (24%), and alcohol abuse (22%).
Median time of steroid administration was 7 months (range,
1 to 24 months). Ninety-one percent of patients were
treated with a calcineurin inhibitors (either cyclosporine or
tacrolimus), while 9% used sirolimus as primary immuno-
suppressant. Arterial hypertension and dyslipidemia were
observed among 52% and 58% of patients, respectively,
with diabetes in 30% and obesity in 20%. The prevalence of
PTMS was 28%, including only 6% before OLT. The peak
incidence for PTMS was observed within 1 year posttrans-
plantation. Diabetes mellitus was the most relevant factor
for the diagnosis of PTMS (95%). Upon multivariate
analysis, diabetes mellitus and overweight or obese be-
fore OLT were independent predictive factors for PTMS.
The use of tacrolimus versus cyclosporine was associated
with a lower incidence of PTMS (21% versus 38%, P 
001). Among our study population, 27% of patients
howed a high cardiovascular risk (78% had PTMS).
ardiovascular events occurred in 6 patients (4% of
otal), the majority of whom were men and belonged to
he PTMS group (Fig 1).
DISCUSSION
This study revealed a 28% rate of PTMS among patients
after liver transplantation, which was less than that reported
in previous studies.3–6 Moreover, the prevalence of dyslip-
demia, diabetes, and arterial hypertension was similar to
hat reported in other studies, but the rate of patients who
ere obese or overweight (20%) was lower in our popula-
ion. With regard to factors predicting PTMS, diabetes
ellitus and patients who were overweight or obese before
LT were independent conditions. These conditions may
elp to achieve early identification of patients with an
igher risk of post-OLT metabolic disturbances. In fact, theajority of the patients developed PTMS during the first
ear after transplantation. At variance with another study,6
we failed to observe a correlation between hepatitis C virus
etiology and PTMS.
The clinical relevance of PTMS in liver transplant recip-
ients is supported by the higher rate of cardiovascular event
among this group.7 Four of 6 patients with a cardiovascular
event in our population also had a diagnosis of PTMS.
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